IRESSA® (gefitinib) Approved by the U.S. Food and Drug Administration for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

ChemDiv’s Discovery Platform Enables Differentiated, Reversible Pan EGFR Kinase Inhibitors for GFR Mutant Lung Cancer

San Diego, CA — September 30, 2025 — ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry,

ChemDiv Extends Discovery and Early Development Partnership with Mondego Bio on Best-in-Class PTPN2 Immuno-Oncology Program